1. Efficacy and safety of inclisiran in patients with established cerebrovascular disease: pooled, post hoc analysis of the ORION-9, ORION-10 and ORION-11, phase 3 randomised clinical trials. (14th October 2021) Authors: Koenig, W; Ray, K K; Kallend, D G; Landmesser, U; Leiter, L A; Schwartz, G G; Wright, R S; Garcia Conde, L; Jaros, M; Raal, F J Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficacy and safety of inclisiran in patients with polyvascular disease: pooled, post hoc analysis of the ORION-9, ORION-10 and ORION-11, phase 3 randomised controlled trials. (14th October 2021) Authors: Koenig, W; Ray, K K; Kallend, D G; Landmesser, U; Leiter, L A; Schwartz, G G; Wright, R S; Garcia Conde, L; Jaros, M; Raal, F J Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Evolocumab treatment reduces carotid intima-media thickness in paediatric patients with heterozygous familial hypercholesterolaemia. (3rd October 2022) Authors: Wiegman, A; Ruzza, A; Hovingh, G K; Santos, R D; Mach, F; Stefanutti, C; Luirink, I; Bridges, I; Wang, B; Bhatia, A K; Raal, F J; Kastelein, J J P; Gaudet, D Journal: European heart journal Issue: Volume 43(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗